All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EBMT 2018 | Comparison of safety outcomes between PTCy-based haploidentical and HLA-matched related or unrelated donor transplantation for patients with R/R aggressive NHL

By Appitha Eakin

Share:

Mar 26, 2018


An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-2 was presented by Sarah Haebe, from the Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, Ludwig-Maximilians University, Munich, Germany which compared the safety and efficacy of post-transplantation cyclophosphamide (PTCy)-based haploidentical donor (haplo-D) transplantation versus HLA-matched related donor (MRD) or unrelated donor (URD) transplantation in refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (aNHL).

In this study, patients treated with T-cell replete (TCR) HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were matched-paired with patients receiving HLA-matched transplantation (MRD and URD). The age (± 5 years) and the stage at HSCT (defined as complete response [CR] or non-CR) varied between pair-matched patients in this analysis. The primary endpoints of this study were overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM) and graft-versus-host disease (GvHD) incidence.

Demographics

  • N = 21 patients in each group (TCR/PTCy haplo-HSCT, MRD and URD)
  • Successful match-pair single center analysis of 21 haplo-HSCT with 21 MRD and 21 URD patients
  • Median age of all patients (range): 48 (20–65)
  • Histology (all patients):
    • Aggressive NHL: 62%
    • Indolent NHL: 22%
    • T-cell NHL (T-NHL): 16%
  • Median number of prior therapies (range): 4 (2–6)
  • Conditioning regimen (all patients):
    • Reduced intensity conditioning (RIC): 58%
    • Non-myeloablative conditioning(NMA): 21%
    • Myeloablative conditioning (MAC): 21%

Key Findings

  • Median follow-up: 39 months
  • CR at Day +30 (all patients) = 84%;
  • Median time to engraftment (days; P = 0.2):
    • MRD = 16
    • URD = 18
    • Haplo = 20
  • PFS and OS at 2-years (%):
    • MRD = 33 and 43
    • URD = 19 and 38
    • Haplo = 43 and 52
  • PFS and OS at 3-years (%):
    • MRD = 29 and 33
    • URD = 19 and 38
    • Haplo = 38 and 52
  • Occurrence of acute GvHD II–IV at 100-days follow-up (%; P = 0.03):
    • MRD = 30
    • URD = 55
    • Haplo = 21
  • Occurrence of chronic GvHD (moderate and severe) at one year follow-up (%; P = 0.4):
    • MRD = 39
    • URD = 35
    • Haplo = 20
  • Non-relapse mortality (NRM) within one year after transplantation (%):
    • MRD = 2
    • URD = 33
    • Haplo = 24
  • Relapse rate within the first year after transplantation (%):
    • MRD = 29
    • URD = 38
    • Haplo = 24
  • Death from aplasia = 6 patients

The results from this study demonstrated similar outcomes between patients treated with haplo-HSCT using PTCy and patients who received HLA-matched transplantation. With a higher incidence of acute GvHD and NRM rates after URD transplantation, the authors suggested that haplo-HSCT might be used as an efficient safer alternative regimen for patients with aNHL.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?